

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 - 14 (Cancelled).

15 (Currently Amended). A method for selecting a subject suffering from a certain inflammatory disease, to receive anti-inflammatory therapeutic treatment that comprises administering to the subject an A₃ adenosine receptor (A₃AR) agonist, the method comprising determining the level of expression of A₃AR in the ~~white~~ white blood cells (WBCs) of the subject and selecting the subject to receive said anti-inflammatory therapeutic treatment if said level is above a predetermined level.

16 (Original). The method of Claim 15, wherein said sample of WBC is taken from a subject before receiving an anti-inflammatory treatment.

17 (Original). The method according to claim 15, wherein the inflammatory state is the result of an autoimmune disease.

18 (Currently Amended). The method according to claim 18₁₇, wherein the autoimmune disease is rheumatoid arthritis (RA).

19 (Original). The method of Claim 15, wherein said anti-inflammatory therapeutic treatment comprises providing said subject with an anti-inflammatory amount of IB-MECA.

20 (Original). The method of Claim 15, for selecting a candidate for receiving anti-inflammatory therapeutic treatment under clinical studies.